Paratek Pharmaceuticals, Inc. (PRTK) financial statements (2023 and earlier)

Company profile

Business Address 75 PARK PLAZA
BOSTON, MA 02116
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:95,500125,200215,400292,800151,700128,000131,302
Cash and cash equivalents80,367105,157102,30246,98735,41652,962131,302
Short-term investments15,10720,005113,077203,364116,30775,076 
Other undisclosed cash, cash equivalents, and short-term investments26382142,449(23)(38) 
Restricted cash and investments1258913242661628172,443
Receivables33,11715,7339,5832495,889323745
Inventory, net of allowances, customer advances and progress billings11,02014,55511,579    
Inventory11,02014,55511,579    
Other undisclosed current assets12,3387,7386,468(38,072)2,7352,9607,927
Total current assets:152,100164,117243,354255,243160,486132,100142,417
Noncurrent Assets
Inventory, Noncurrent27,767      
Operating lease, right-of-use asset1,7572,0102,514
Property, plant and equipment7949641,2271,1731,7111,188779
Long-term investments and receivables   42,487   
Long-term investments   42,487   
Intangible assets, net (including goodwill)8298298298299711,8442,178
Goodwill829829829829829829829
Intangible assets, net (excluding goodwill)    1421,0151,349
Restricted cash and investments125 3,007249250250250
Other noncurrent assets4978,933148211280350294
Total noncurrent assets:31,76912,7367,72544,9493,2123,6323,501
TOTAL ASSETS:183,869176,853251,079300,192163,698135,732145,918
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities28,84022,63920,81215,22514,6298,4433,097
Accounts payable5,3941,8134,1162,0903,5554,418766
Accrued liabilities23,44620,82616,69613,13511,0741,4161,008
Employee-related liabilities     2,6091,323
Other liabilities2,4571,3143,388    
Other undisclosed current liabilities   2,4842,16011,96917,405
Total current liabilities:31,29723,95324,20017,70916,78920,41220,502
Noncurrent Liabilities
Long-term debt and lease obligation255,736252,018262,823228,95959,18638,97419,565
Long-term debt, excluding current maturities254,428250,474260,728228,95959,18638,97419,565
Operating lease, liability1,3081,5442,095
Liabilities, other than long-term debt24,6233,1423,7035,9465,2454,7544,611
Accounts payable and accrued liabilities21,846      
Other liabilities2,7773,1423,7035,9465,1744,0993,611
Business combination, contingent consideration, liability    716551,000
Total noncurrent liabilities:280,359255,160266,526234,90564,43143,72824,176
Total liabilities:311,656279,113290,726252,61481,22064,14044,678
Stockholders' equity
Stockholders' equity attributable to parent(127,787)(102,260)(39,647)47,57882,47871,592101,240
Common stock52464032282317
Additional paid in capital739,053705,489671,497630,142552,720451,947369,949
Accumulated other comprehensive income (loss)(9)474(128)(158)(16) 
Accumulated deficit(866,883)(807,799)(711,258)(582,468)(470,112)(380,362)(268,726)
Total stockholders' equity:(127,787)(102,260)(39,647)47,57882,47871,592101,240
TOTAL LIABILITIES AND EQUITY:183,869176,853251,079300,192163,698135,732145,918

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues130,16246,92416,54417,11712,61629 
Revenue, net12,61629 
Cost of revenue(21,535)(8,651)(3,484)    
Gross profit:108,62738,27313,06017,11712,61629 
Operating expenses(149,757)(113,777)(128,689)(121,273)(97,780)(109,860)(73,613)
Other undisclosed operating income   715843453,560
Operating loss:(41,130)(75,504)(115,629)(104,085)(84,580)(109,486)(70,053)
Nonoperating income (expense)541,5713,5743,2161,3431,073(37)
Investment income, nonoperating661,5153,5743,2601,3771,069(37)
Other nonoperating income (expense)(12)56 (44)(34)4 
Interest and debt expense(17,408)(22,608)(16,403)(10,985)(5,079)(3,223) 
Loss from continuing operations before equity method investments, income taxes:(58,484)(96,541)(128,458)(111,854)(88,316)(111,636)(70,090)
Other undisclosed loss from continuing operations before income taxes  (31)    
Loss from continuing operations before income taxes:(58,484)(96,541)(128,489)(111,854)(88,316)(111,636)(70,090)
Income tax expense(600) (301)(502)(753)  
Net loss:(59,084)(96,541)(128,790)(112,356)(89,069)(111,636)(70,090)
Other undisclosed net loss attributable to parent      (770)
Net loss available to common stockholders, diluted:(59,084)(96,541)(128,790)(112,356)(89,069)(111,636)(70,860)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(59,084)(96,541)(128,790)(112,356)(89,069)(111,636)(70,090)
Other comprehensive income (loss)(13)(70)20230(142)(16) 
Comprehensive loss, net of tax, attributable to parent:(59,097)(96,611)(128,588)(112,326)(89,211)(111,652)(70,090)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: